Directed Studies Sample Clauses

Directed Studies. A Directed Studies course shall be provided on a voluntary basis as an addition to an individual faculty member’s assigned workload. This course will be provided by agreement of the faculty member, Chair, and Xxxx, and will have a maximum of five (5) students. The faculty member shall receive two-hundred and fifty dollars ($250) per semester for each Directed Studies student for a 3 credit course. Where a Directed Studies course has fewer or greater than three credit hours, actual payment for each Directed Studies student enrolled in the course will be pro-rated. For example, faculty will receive $83.34 ($250/3) per semester for each Directed Studies student enrolled in a one credit course; $125.00 ($250/2) for a 1.5 credit course; $166.67 ($250 x 2/3) for a two-credit course; $333.34 (250 x 4/3) for a four-credit course, etc. The Xxxx will identify Directed Studies on the workload report.
Sample 1Sample 2Sample 3See All (14)
AutoNDA by SimpleDocs
Directed Studies. Research Faculty assigned this type of Directed Studies course shall undertake the supervision of a student who engages in a directed investigation of a research problem that involved generation of original data.
Sample 1Sample 2Sample 3See All (9)
Directed Studies. Readings Faculty assigned this type of Directed Studies course shall undertake the supervision of a student who conducts an in-depth literature review of a selected topic in an area in which the college professor is qualified.
Sample 1Sample 2Sample 3See All (9)
Directed Studies. The member shall not obtain additional load for directed study students who are attending any of the member’s regularly scheduled classes.
Sample 1Sample 2Sample 3See All (4)
Directed Studies. When considered an overload, the faculty member shall be reimbursed at one-sixth of the comparable part-time rate for the first directed study student and then $50 per student credit for each additional student.
Sample 1Sample 2Sample 3
Directed Studies. 18.9.1 Adjunct professors shall be compensated for assigned teaching of a Directed Study at the rate of 1/12 x per unit pay rate x units.
Sample 1Sample 2
Directed Studies. A Directed Studies course shall be provided on a voluntary basis as an addition to an individual faculty member’s assigned workload. This course will be provided by agreement of the faculty member, Chair, and Xxxx, and will have a maximum of five
Sample 1
AutoNDA by SimpleDocs
Directed Studies. 1) Applications for Directed Studies (499-level work) from eligible students, with all documentation, will be forwarded to the Xxxx or designate who will:
Sample 1
Directed Studies. Attached Supervision Faculty assigned this type of Directed Studies course shall undertake the supervision of a student who is engaged in an activity which is a required component of a course but which involved the additional supervision of another College professor. may assign students in a Directed Studies course to a maximum of four students at any one time, subject to the agreements of parties outlined in clause (1 Directed Studies courses shall be assigned a workload credit as follows: Instructional Hours Each hour scheduled in the course or program timetable for a directed studies course shall count as an instructional hour, to a minimum of one hour and a maximum of three hours. Course Preparations Each credit assigned the course shall equate to one hour of course preparation, unless the College professor, Department Chair and designated supervisor agree that the course is sufficiently similar to another course assigned to the College professor's current workload.
Sample 1

Related to Directed Studies

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Special Studies Providing planning services, site evaluations, environmental studies, or comparative studies of prospective sites, preparing special surveys, studies, and submissions required under Applicable Law.

  • Annual Production Program document describing the forecasts for Production and handling of Oil, Gas, water, special fluids, and waste arising from the Production process of each Development Area or Field.

Time is Money Join Law Insider Premium to draft better contracts faster.